Recruiting

Moda-flx Hemodialysis System for End Stage Kidney Disease

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Moda-flx Hemodialysis System™

Device
Who is being recruted

Urogenital Diseases+10

+ Chronic Disease

+ Female Urogenital Diseases and Pregnancy Complications

From 18 to 80 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: October 2025
See protocol details

Summary

Principal SponsorDiality Inc.
Study ContactMichael Gastauer
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: October 6, 2025

Actual date on which the first participant was enrolled.

This study is designed to test a new hemodialysis machine called the Moda-flx Hemodialysis System™. It focuses on people with End Stage Kidney Disease (ESKD) who are already receiving regular dialysis treatments. The study aims to see how safe and effective this machine is when used both in a professional healthcare setting and at home by the patients themselves or with the help of a trained caregiver. This research is important as it could offer more flexibility and convenience for patients, potentially improving their quality of life by allowing them to perform dialysis treatments at home. Participants in this study will use the Moda-flx machine as part of their regular dialysis routine. The study will observe how well the machine works in removing waste from the blood and keeping patients healthy. It also looks at how easy and safe it is for patients and their caregivers to use the machine at home. There are no specific risks or benefits mentioned, but the study aims to ensure that the machine is both effective and user-friendly in different settings.

Official TitleProspective, Non-Randomized, Multicenter, Open-Label Study Evaluating the Use of the Moda-flx Hemodialysis System™ Under Professional Care and At Home by Participants With End Stage Kidney Disease (ESKD) Who Are on Stable Dialysis Regimens
NCT06613568
Principal SponsorDiality Inc.
Study ContactMichael Gastauer
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

50 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesChronic DiseaseFemale Urogenital Diseases and Pregnancy ComplicationsKidney DiseasesKidney Failure, ChronicPathologic ProcessesPathological Conditions, Signs and SymptomsUrologic DiseasesDisease AttributesRenal Insufficiency, ChronicRenal InsufficiencyFemale Urogenital DiseasesMale Urogenital Diseases

Criteria

Inclusion Criteria: * Are between 18 and 80 years of age and Care Partner is at least 18 years of age at the time of signing consent. * Have a diagnosis of end stage kidney disease (ESKD) adequately treated by maintenance dialysis (defined as achieving a spKt/V ≥ 1.2 OR stdKt/V ≥ 2.1) and be deemed stable by their treating nephrologist prior to the end of the Screening Period * Have a well-functioning and stable vascular access (tunneled central venous catheter arteriovenous fistula, or graft) that allows a blood flow of at least 300 ml/min prior to the end of Screening * Can successfully complete a Skills and Comprehension Assessment with a Care Partner prior to the completion of the Training Period. Exclusion Criteria: * Hgb level of \< 9 g/dL at Screening * Symptomatic intradialytic hypotension requiring medical intervention (ultrafiltration turned off, bolus of fluid) in at least two treatments during the Run-In period defined as: 1. Persistent pre-dialysis sitting SBP \< 100 mmHg despite medical therapy, 2. Nadir intradialytic Systolic Blood Pressure (SBP) \< 90 mmHg, if Subject's pre-HD SBP \< 160 mmHg 3. Nadir intradialytic SBP \< 100 mmHg if Subject's pre-HD SBP ≥ 160 mmHg * Documented history of non-adherence to dialysis therapy that would prevent successful completion of the study * Participant had an average ultrafiltration rate \> 13 mL/kg/hour during the last 2 weeks prior to Screening, per medical records. * Had a significant cardiovascular adverse event within the last 90 days prior to Screening.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Participants will receive dialysis therapy using the Moda-Flx Hemodialysis System™ in a Professional Care setting and At Home setting

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 4 locations

Recruiting

North America Research Institute

San Dimas, United StatesOpen North America Research Institute in Google Maps
Recruiting

Nephrology Associates of Knoxville

Knoxville, United States
Recruiting

aQua Research Institute, LLC

Houston, United States
Recruiting

University of Washington

Seattle, United States
Recruiting
4 Study Centers